About this Journal Submit a Manuscript Table of Contents 
Stroke Research and Treatment
Volume 2011 (2011), Article ID 607852, 23 pages
doi:10.4061/2011/607852
Review Article

Antithrombotic Medication for Cardioembolic Stroke Prevention

M. Àngels Font,1,2 Jerzy Krupinski,3 and Adrià Arboix4

1Institut d'Investigacions Biomèdiques de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain
2Department of Neurology, Hospital Sant Joan de Déu de Manresa (Fundació Althaia), Catalonia, 08243 Manresa, Spain
3Department of Neurology, Cerebrovascular Diseases Unit, Hospital Universitari Mútua de Terrassa, Catalonia, 08227 Terrassa, Spain
4Cerebrovascular Division, Department of Neurology, Hospital Universitari Sagrat Cor, University of Barcelona, C/Viladomat 288, Catalonia, 08029 Barcelona, Spain

Received 6 July 2010; Revised 2 March 2011; Accepted 27 March 2011

Academic Editor: Stefano Ricci

Copyright © 2011 M. Àngels Font et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Sacco, R. Adams, G. Albers et al., “Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline,” Stroke, vol. 37, no. 2, pp. 577–617, 2006. View at Publisher · View at Google Scholar · View at PubMed
  2. P. Amarenco, A. Cohen, C. Tzourio et al., “Atherosclerotic disease of the aortic arch and the risk of ischemic stroke,” New England Journal of Medicine, vol. 331, no. 22, pp. 1474–1479, 1994. View at Publisher · View at Google Scholar · View at PubMed
  3. A. Arboix and J. L. Martí-Vilalta, “Presumed cardioembolic lacunar infarcts,” Stroke, vol. 23, no. 12, pp. 1841–1842, 1992. View at Scopus
  4. J. Lodder, J. M. Bamford, P. A. G. Sandercock, L. N. Jones, and C. P. Warlow, “Are hypertension or cardiac embolism likely causes of lacunar infarction?” Stroke, vol. 21, no. 3, pp. 375–381, 1990. View at Scopus
  5. C. M. Fisher, “Capsular infarcts: the underlying vascular lesions,” Archives of Neurology, vol. 36, no. 2, pp. 65–73, 1979. View at Scopus
  6. “Guidelines for management of ischaemic stroke and transient ischaemic attack 2008,” Cerebrovascular Diseases, vol. 25, no. 5, pp. 457–507, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Cervera, S. Amaro, V. Obach, and A. Chamorro, “Prevention of ischemic stroke: antithrombotic therapy in cardiac embolism,” Current Drug Targets, vol. 8, no. 7, pp. 824–831, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. D. S. Whitlon, J. A. Sadowski, and J. W. Suttie, “Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition,” Biochemistry, vol. 17, no. 8, pp. 1371–1377, 1978. View at Scopus
  9. S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine, “Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, supplement 6, pp. 257S–298S, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. V. Fuster, L. E. Rydén, D. S. Cannom et al., “ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation),” Journal of the American College of Cardiology, vol. 48, no. 4, pp. 854–906, 2006. View at Publisher · View at Google Scholar · View at PubMed
  11. A. S. Go, E. M. Hylek, K. A. Phillips et al., “Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study,” Journal of the American Medical Association, vol. 285, no. 18, pp. 2370–2375, 2001.
  12. D. C. Anderson, L. J. Kappelle, M. Eliasziw, V. L. Babikian, L. A. Pearce, and H. J. M. Barnett, “Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis,” Stroke, vol. 33, no. 8, pp. 1963–1967, 2002. View at Publisher · View at Google Scholar
  13. R. G. Hart, O. Benavente, R. McBride, and L. A. Pearce, “Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis,” Annals of Internal Medicine, vol. 131, no. 7, pp. 492–501, 1999.
  14. G. Y. H. Lip and S. J. Edwards, “Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis,” Thrombosis Research, vol. 118, no. 3, pp. 321–333, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning, “Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, supplement 3, pp. 429S–456S, 2004. View at Publisher · View at Google Scholar
  16. P. A. Wolf, T. R. Dawber, H. E. Thomas Jr., and W. B. Kannel, “Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study,” Neurology, vol. 28, no. 10, pp. 973–977, 1978.
  17. Atrial Fibrillation Investigators, “Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials,” Archives of Internal Medicine, vol. 154, no. 13, pp. 1449–1457, 1994. View at Publisher · View at Google Scholar
  18. European Atrial Fibrillation Trial Study Group, “Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke,” Lancet, vol. 342, no. 8882, pp. 1255–1262, 1993.
  19. Atrial Fibrillation Investigators, “Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials,” Archives of Internal Medicine, vol. 154, no. 13, pp. 1449–1457, 1994. View at Publisher · View at Google Scholar
  20. “The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The atrial fibrillation investigators,” Archives of Internal Medicine, vol. 157, no. 11, pp. 1237–1240, 1997.
  21. G. W. Albers, “Atrial fibrillation and stroke: three new studies, three remaining questions,” Archives of Internal Medicine, vol. 154, no. 13, pp. 1443–1448, 1994. View at Publisher · View at Google Scholar
  22. C. Van Walraven, R. G. Hart, D. E. Singer et al., “Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis,” Journal of the American Medical Association, vol. 288, no. 19, pp. 2441–2448, 2002. View at Publisher · View at Google Scholar
  23. Stroke Prevention in Atrial Fibrillation Investigators, “Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the stroke prevention in atrial fibrillation study,” Journal of Stroke and Cerebrovascular Diseases, vol. 5, no. 3, pp. 147–157, 1995.
  24. Stroke Prevention in Atrial Fibrillation Investigators, “Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial,” Lancet, vol. 348, no. 9028, pp. 633–638, 1996.
  25. F. Dentali, J. D. Douketis, W. Lim, and M. Crowther, “Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials,” Archives of Internal Medicine, vol. 167, no. 2, pp. 117–124, 2007. View at Publisher · View at Google Scholar · View at PubMed
  26. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators, “Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study,” Journal of the American Medical Association, vol. 279, no. 16, pp. 1237–1277, 1998.
  27. ACTIVE Investigators, “Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial,” Lancet, vol. 367, no. 9526, pp. 1903–1912, 2006.
  28. S. J. Connolly, J. Pogue, R. G. Hart et al., “Effect of clopidogrel added to aspirin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 360, no. 20, pp. 2066–2078, 2009. View at Publisher · View at Google Scholar · View at PubMed
  29. B. F. Gage, A. D. Waterman, W. Shannon, M. Boechler, M. W. Rich, and M. J. Radford, “Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation,” Journal of the American Medical Association, vol. 285, no. 22, pp. 2864–2870, 2001.
  30. T. J. Wang, J. M. Massaro, D. Levy et al., “A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study,” Journal of the American Medical Association, vol. 290, no. 8, pp. 1049–1056, 2003. View at Publisher · View at Google Scholar · View at PubMed
  31. Stroke Risk in Atrial Fibrillation Working Group, “Independent predictors of stroke in patients with atrial fibrillation: a systematic review,” Neurology, vol. 69, no. 6, pp. 546–554, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. A. A. Jarquin-Valdivia, E. F. Wijdicks, and C. McGregor, “Neurologic complications following heart transplantation in the modern era: decreased incidence, but postoperative stroke remains prevalent,” Transplantation Proceedings, vol. 31, no. 5, pp. 2161–2162, 1999. View at Publisher · View at Google Scholar
  33. R. Belvís, J. Martí-Fàbregas, D. Cocho et al., “Cerebrovascular disease as a complication of cardiac transplantation,” Cerebrovascular Diseases, vol. 19, no. 4, pp. 267–271, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. J. J. Ricotta, G. L. Faggioli, A. Castilone, and J. M. Hassett, “Risk factors for stroke after cardiac surgery: Buffalo Cardiac-Cerebral Study Group,” Journal of Vascular Surgery, vol. 21, no. 2, pp. 359–364, 1995. View at Publisher · View at Google Scholar
  35. B. F. Gage, Y. Yan, P. E. Milligan et al., “Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF),” American Heart Journal, vol. 151, no. 3, pp. 713–719, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. E. M. Hylek and D. E. Singer, “Risk factors for intracranial hemorrhage in outpatients taking warfarin,” Annals of Internal Medicine, vol. 120, no. 11, pp. 897–902, 1994.
  37. L. B. Goldstein, R. Adams, M. J. Alberts et al., “Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline,” Stroke, vol. 37, no. 6, pp. 1583–1633, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. E. M. Hylek, S. J. Skates, M. A. Sheehan, and D. E. Singer, “An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation,” New England Journal of Medicine, vol. 335, no. 8, pp. 540–546, 1996. View at Publisher · View at Google Scholar · View at PubMed
  39. G. P. Samsa, D. B. Matchar, L. B. Goldstein et al., “Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities,” Archives of Internal Medicine, vol. 160, no. 7, pp. 967–973, 2000.
  40. T. J. Bungard, M. L. Ackman, G. Ho, and R. T. Tsuyuki, “Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital,” Pharmacotherapy, vol. 20, no. 9, pp. 1060–1065, 2000.
  41. B. F. Gage, C. Van Walraven, L. Pearce et al., “Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin,” Circulation, vol. 110, no. 16, pp. 2287–2292, 2004. View at Publisher · View at Google Scholar · View at PubMed
  42. L. Kalra and G. Y. Lip, “Guideline Development Group for the NICE clinical guideline for the management of atrial fibrillation. Antithrombotic treatment in atrial fibrillation,” Heart, vol. 93, no. 1, pp. 39–44, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. The Atrial Fibrillation Followup Investigation of Rhythm Management Investigators, “A comparison of rate control and rhythm control in patients with atrial fibrillation,” New England Journal of Medicine, vol. 347, no. 23, pp. 1825–1833, 2002.
  44. E. M. Hylek, A. S. Go, Y. Chang et al., “Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation,” New England Journal of Medicine, vol. 349, no. 11, pp. 1019–1026, 2003. View at Publisher · View at Google Scholar · View at PubMed
  45. A. Rash, T. Downes, R. Portner, W. W. Yeo, N. Morgan, and K. S. Channer, “A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO),” Age and Ageing, vol. 36, no. 2, pp. 151–156, 2007. View at Publisher · View at Google Scholar · View at PubMed
  46. J. Mant, F. D. Hobbs, K. Fletcher et al., “Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial,” Lancet, vol. 370, no. 9586, pp. 493–503, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. J. Herlitz, J. Holm, M. Peterson, B. W. Karlson, M. H. Evander, and L. Erhardt, “Factors associated with development of stroke long-term after myocardial infarction: experiences from the LoWASA trial,” Journal of Internal Medicine, vol. 257, no. 2, pp. 201–207, 2005. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Behar, D. Tanne, E. Abinader et al., “Cerebrovascular accident complicating acute myocardial infarction: incidence, clinical significance, and short- and long-term mortality rates. The SPRINT Study Group,” American Journal of Medicine, vol. 91, no. 1, pp. 45–50, 1991. View at Publisher · View at Google Scholar
  49. M. A. Sloan, T. R. Price, M. L. Terrin et al., “Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction: the TIMI-II pilot and randomized clinical trial combined experience,” Stroke, vol. 28, no. 6, pp. 1107–1114, 1997.
  50. H. Kassem-Moussa, K. W. Mahaffey, C. Graffagnino et al., “Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome,” American Heart Journal, vol. 148, no. 3, pp. 439–446, 2004. View at Publisher · View at Google Scholar · View at PubMed
  51. J. S. Saczynski, F. A. Spencer, J. M. Gore et al., “Twenty-year trends in the incidence of stroke complicating acute myocardial infarction: Worcester Heart Attack Study,” Archives of Internal Medicine, vol. 168, no. 19, pp. 2104–2110, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. B. J. Witt, R. D. Brown Jr., S. J. Jacobsen, S. A. Weston, B. P. Yawn, and V. L. Roger, “A community-based study of stroke incidence after myocardial infarction,” Annals of Internal Medicine, vol. 143, no. 11, pp. 785–792, 2005.
  53. T. Mooe, B. O. Olofsson, B. Stegmayr, and P. Eriksson, “Ischemic stroke: impact of a recent myocardial infarction,” Stroke, vol. 30, no. 5, pp. 997–1001, 1999.
  54. Z. G. Nadareishvili, Z. Choudary, C. Joyner, D. Brodie, and J. W. Norris, “Cerebral microembolism in acute myocardial infarction,” Stroke, vol. 30, no. 12, pp. 2679–2682, 1999.
  55. E. Loh, M. S. Sutton, C. C. Wun et al., “Ventricular dysfunction and the risk of stroke after myocardial infarction,” New England Journal of Medicine, vol. 336, no. 4, pp. 251–257, 1997. View at Publisher · View at Google Scholar · View at PubMed
  56. Anonymous, “ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group,” Lancet, vol. 339, no. 8796, pp. 753–770, 1992.
  57. A. P. Maggioni, M. G. Franzosi, E. Santoro, et al., “The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and the International Study Group,” New England Journal of Medicine, vol. 327, no. 1, pp. 1–6, 1992.
  58. Anonymous, “An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators,” New England Journal of Medicine, vol. 329, no. 10, pp. 673–682, 1993. View at Publisher · View at Google Scholar · View at PubMed
  59. E. Van de Graaff, M. Dutta, P. Das et al., “Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction,” Stroke, vol. 37, no. 10, pp. 2546–2551, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. Anonymous, “Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group,” Lancet, vol. 2, no. 8607, pp. 349–360, 1988.
  61. A. J. Azar, P. J. Koudstaal, A. R. Wintzen, P. F. Van Bergen, J. J. Jonker, and J. W. Deckers, “Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction,” Annals of Neurology, vol. 39, no. 3, pp. 301–307, 1996. View at Publisher · View at Google Scholar · View at PubMed
  62. L. D. Fiore, M. D. Ezekowitz, M. T. Brophy, D. Lu, J. Sacco, and P. Peduzzi, “Department of veterans affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study,” Circulation, vol. 105, no. 5, pp. 557–563, 2002. View at Publisher · View at Google Scholar
  63. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen, “Warfarin, aspirin, or both after myocardial infarction,” New England Journal of Medicine, vol. 347, no. 13, pp. 969–974, 2002. View at Publisher · View at Google Scholar · View at PubMed
  64. R. F. Van Es, J. J. Jonker, F. W. Verheugt, J. W. Deckers, and D. E. Grobbee, “Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial,” Lancet, vol. 360, no. 9327, pp. 109–113, 2002. View at Publisher · View at Google Scholar · View at PubMed
  65. C. A. Visser, G. Kan, R. S. Meltzer, K. I. Lie, and D. Durrer, “Long-term follow-up of left ventricular thrombus after acute myocardial infarction. A two-dimensional echocardiographic study in 96 patients,” Chest, vol. 86, no. 4, pp. 532–536, 1984.
  66. T. Huynh, J. L. Cox, D. Massel et al., “Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project,” American Heart Journal, vol. 148, no. 1, pp. 86–91, 2004. View at Publisher · View at Google Scholar · View at PubMed
  67. B. M. Massie and N. B. Shah, “Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management,” American Heart Journal, vol. 133, no. 6, pp. 703–712, 1997. View at Publisher · View at Google Scholar
  68. S. D. Katz, P. R. Marantz, L. Biasucci et al., “Low incidence of stroke in ambulatory patients with heart failure: a prospective study,” American Heart Journal, vol. 126, no. 1, pp. 141–146, 1993.
  69. V. Fuster, B. J. Gersh, E. R. Giuliani, A. J. Tajik, R. O. Brandenburg, and R. L. Frye, “The natural history of idiopathic dilated cardiomyopathy,” American Journal of Cardiology, vol. 47, no. 3, pp. 525–531, 1981.
  70. P. T. Vaitkus and E. S. Barnathan, “Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis,” Journal of the American College of Cardiology, vol. 22, no. 4, pp. 1004–1009, 1993.
  71. P. Petersen, G. Boysen, J. Godtfredsen, E. D. Andersen, and B. Andersen, “Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study,” Lancet, vol. 1, no. 8631, pp. 175–179, 1989.
  72. D. L. Dries, M. J. Domanski, M. A. Waclawiw, and B. J. Gersh, “Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure,” American Journal of Cardiology, vol. 79, no. 7, pp. 909–913, 1997. View at Publisher · View at Google Scholar
  73. P. Pullicino, J. L. Thompson, B. Barton, B. Levin, S. Graham, and R. S. Freudenberger, “Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design,” Journal of Cardiac Failure, vol. 12, no. 1, pp. 39–46, 2006. View at Publisher · View at Google Scholar · View at PubMed
  74. N. Coulshed, E. J. Epstein, C. S. McKendrick, R. W. Galloway, and E. Walker, “Systemic embolism in mitral valve disease,” British Heart Journal, vol. 32, no. 1, pp. 26–34, 1970.
  75. P. Wood, “An appreciation of mitral stenosis. I. Clinical features,” British Medical Journal, vol. 1, no. 4870, pp. 1051–1063, 1954.
  76. J. C. Rowe, E. F. Bland, H. B. Sprague, and P. D. White, “The course of mitral stenosis without surgery: ten- and twenty-year perspectives,” Annals of Internal Medicine, vol. 52, pp. 741–749, 1960.
  77. W. S. Abernathy and P. W. Willis III, “Thromboembolic complications of rheumatic heart disease,” Cardiovascular Clinics, vol. 5, no. 2, pp. 131–175, 1973.
  78. R. Daley, T. W. Mattingly, C. L. Holt, E. F. Bland, and P. D. White, “Systemic arterial embolism in rheumatic heart disease,” American Heart Journal, vol. 42, no. 4, pp. 566–581, 1951.
  79. G. F. Adams, J. D. Merrett, W. M. Hutchinson, and A. M. Pollock, “Cerebral embolism and mitral stenosis: survival with and without anticoagulants,” Journal of Neurology Neurosurgery and Psychiatry, vol. 37, no. 4, pp. 378–383, 1974.
  80. “Stroke Prevention in Atrial Fibrillation Study: final results,” Circulation, vol. 84, no. 2, pp. 527–539, 1991.
  81. M. D. Ezekowitz, S. L. Bridgers, K. E. James et al., “Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators,” New England Journal of Medicine, vol. 327, no. 20, pp. 1406–1412, 1992.
  82. P. W. M. Fedak, S. Verma, T. E. David, R. L. Leask, R. D. Weisel, and J. Butany, “Clinical and pathophysiological implications of a bicuspid aortic valve,” Circulation, vol. 106, no. 8, pp. 900–904, 2002. View at Publisher · View at Google Scholar
  83. M. Ferencik and L. A. Pape, “Changes in size of ascending aorta and aortic valve function with time in patients with congenitally bicuspid aortic valves,” American Journal of Cardiology, vol. 92, no. 1, pp. 43–46, 2003. View at Publisher · View at Google Scholar
  84. P. Wood, “An appreciation of mitral stenosis. I. Clinical features,” British Medical Journal, vol. 1, no. 4870, pp. 1051–1063, 1954.
  85. J. C. Rowe, E. F. Bland, H. B. Sprague, and P. D. White, “The course of mitral stenosis without surgery: ten- and twenty-year perspectives,” Annals of Internal Medicine, vol. 52, pp. 741–749, 1960.
  86. H. J. Levine, S. G. Pauker, and E. W. Salzman, “Antithrombotic therapy in valvular heart disease,” Chest, vol. 95, supplement 2, pp. 98S–106S, 1989.
  87. C. Gohlke-Bürwolf, J. Acar, C. Oakley et al., “Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology,” European Heart Journal, vol. 16, no. 10, pp. 1320–1330, 1995.
  88. D. N. Salem, P. D. Stein, A. Al-Ahmad et al., “Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, supplement 3, pp. 457S–482S, 2004. View at Publisher · View at Google Scholar
  89. R. O. Bonow, B. A. Carabello, C. Kanu et al., “ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons,” Circulation, vol. 114, no. 5, pp. e84–e231, 2006. View at Publisher · View at Google Scholar · View at PubMed
  90. E. M. Baudet, V. Puel, J. T. McBride et al., “Long-term results of valve replacement with the St. Jude Medical prosthesis,” Journal of Thoracic and Cardiovascular Surgery, vol. 109, no. 5, pp. 858–870, 1995. View at Publisher · View at Google Scholar
  91. W. Vongpatanasin, L. D. Hillis, and R. A. Lange, “Prosthetic heart valves,” New England Journal of Medicine, vol. 335, no. 6, pp. 407–416, 1996. View at Publisher · View at Google Scholar · View at PubMed
  92. G. L. Grunkemeier, H. H. Li, D. C. Naftel, A. Starr, and S. H. Rahimtoola, “Long-term performance of heart valve prostheses,” Current Problems in Cardiology, vol. 25, no. 2, pp. 73–154, 2000.
  93. S. C. Cannegieter, F. R. Rosendaal, and E. Briet, “Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses,” Circulation, vol. 89, no. 2, pp. 635–641, 1994.
  94. S. C. Cannegieter, F. R. Rosendaal, A. R. Wintzen, F. J. van der Meer, J. P. Vandenbroucke, and E. Briet, “Optimal oral anticoagulant therapy in patients with mechanical heart valves,” New England Journal of Medicine, vol. 333, no. 1, pp. 11–17, 1995. View at Publisher · View at Google Scholar · View at PubMed
  95. E. G. Butchart, P. A. Lewis, J. A. Bethel, and I. M. Breckenridge, “Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve,” Circulation, vol. 84, pp. III61–III69, 1991.
  96. D. Horstkotte, H. Schulte, W. Bircks, and B. Strauer, “Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude Medical prostheses,” The Journal of Heart Valve Disease, vol. 2, no. 3, pp. 291–301, 1993.
  97. J. Acar, B. Iung, J. P. Boissel et al., “AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves,” Circulation, vol. 94, no. 9, pp. 2107–2112, 1996.
  98. P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G. Turpie, “Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves,” Chest, vol. 119, supplement 1, pp. 220S–227S, 2001.
  99. A. S. Al-Khadra, D. N. Salem, W. M. Rand, J. E. Udelson, J. J. Smith, and M. A. Konstam, “Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction,” Journal of the American College of Cardiology, vol. 31, no. 4, pp. 749–753, 1998. View at Publisher · View at Google Scholar
  100. S. S. Meschengieser, C. G. Fondevila, J. Frontroth, M. T. Santarelli, and M. A. Lazzari, “Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves,” Journal of Thoracic and Cardiovascular Surgery, vol. 113, no. 5, pp. 910–916, 1997. View at Publisher · View at Google Scholar
  101. D. Gilon, F. S. Buonanno, M. M. Joffe et al., “Lack of evidence of an association between mitral-valve prolapse and stroke in young patients,” New England Journal of Medicine, vol. 341, no. 1, pp. 8–13, 1999. View at Publisher · View at Google Scholar · View at PubMed
  102. L. A. Freed, E. J. Benjamin, D. Levy et al., “Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study,” Journal of the American College of Cardiology, vol. 40, no. 7, pp. 1298–1304, 2002. View at Publisher · View at Google Scholar
  103. L. A. Freed, D. Levy, R. A. Levine et al., “Prevalence and clinical outcome of mitral-valve prolapse,” New England Journal of Medicine, vol. 341, no. 1, pp. 1–7, 1999. View at Publisher · View at Google Scholar · View at PubMed
  104. R. L. Sacco, R. Adams, G. Albers et al., “Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline,” Stroke, vol. 37, no. 2, pp. 577–617, 2006. View at Publisher · View at Google Scholar · View at PubMed
  105. “Preliminary report of the Stroke Prevention in Atrial Fibrillation Study,” New England Journal of Medicine, vol. 322, no. 12, pp. 863–868, 1990.
  106. S. E. Rosen, J. S. Borer, C. Hochreiter et al., “Natural history of the asymptomatic/minimally symptomatic patient with severe mitral regurgitation secondary to mitral valve prolapse and normal right and left ventricular performance,” American Journal of Cardiology, vol. 74, no. 4, pp. 374–380, 1994. View at Publisher · View at Google Scholar
  107. G. M. McKhann, M. A. Goldsborough, L. M. Borowicz Jr. et al., “Predictors of stroke risk in coronary artery bypass patients,” Annals of Thoracic Surgery, vol. 63, no. 2, pp. 516–521, 1997. View at Publisher · View at Google Scholar
  108. O. A. Selnes and G. M. McKhann, “Coronary-artery bypass surgery and the brain,” New England Journal of Medicine, vol. 344, no. 6, pp. 451–452, 2001. View at Publisher · View at Google Scholar · View at PubMed
  109. J. Bucerius, J. F. Gummert, M. A. Borger et al., “Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients,” Annals of Thoracic Surgery, vol. 75, no. 2, pp. 472–478, 2003. View at Publisher · View at Google Scholar
  110. T. F. Floyd, P. Shah, C. C. Price et al., “Clinically silent cerebral ischemic events after cardiac surgery: their incidence, regional vascular occurrence, and procedural dependence,” Annals of Thoracic Surgery, vol. 81, no. 6, pp. 2160–2166, 2006. View at Publisher · View at Google Scholar · View at PubMed
  111. G. W. Roach, M. Kanchuger, C. M. Mangano et al., “Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators,” New England Journal of Medicine, vol. 335, no. 25, pp. 1857–1863, 1996. View at Publisher · View at Google Scholar · View at PubMed
  112. G. K. Peel, S. C. Stamou, M. K. Dullum et al., “Chronologic distribution of stroke after minimally invasive versus conventional coronary artery bypass,” Journal of the American College of Cardiology, vol. 43, no. 5, pp. 752–756, 2004. View at Publisher · View at Google Scholar · View at PubMed
  113. J. Bucerius, J. F. Gummert, M. A. Borger et al., “Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients,” Annals of Thoracic Surgery, vol. 75, no. 2, pp. 472–478, 2003. View at Publisher · View at Google Scholar
  114. A. Z. Segal, W. B. Abernethy, I. F. Palacios, R. BeLue, and G. Rordorf, “Stroke as a complication of cardiac catheterization: risk factors and clinical features,” Neurology, vol. 56, no. 7, pp. 975–977, 2001.
  115. K. A. Büsing, C. Schulte-Sasse, S. Flüchter et al., “Cerebral infarction: incidence and risk factors after diagnostic and interventional cardiac catheterization—prospective evaluation at diffusion-weighted MR imaging,” Radiology, vol. 235, no. 1, pp. 177–183, 2005. View at Publisher · View at Google Scholar · View at PubMed
  116. C. Oezbek, A. Heisel, M. Voelk et al., “Management of stroke complicating cardiac catheterization with recombinant tissue-type plasminogen activator,” American Journal of Cardiology, vol. 76, no. 10, pp. 733–735, 1995. View at Publisher · View at Google Scholar
  117. P. N. Malani, D. B. Dyke, F. D. Pagani, and C. E. Chenoweth, “Nosocomial infections in left ventricular assist device recipients,” Clinical Infectious Diseases, vol. 34, no. 10, pp. 1295–1300, 2002. View at Publisher · View at Google Scholar · View at PubMed
  118. R. B. Libman, E. Wirkowski, M. Neystat, W. Barr, S. Gelb, and M. Graver, “Stroke associated with cardiac surgery. Determinants, timing, and stroke subtypes,” Archives of Neurology, vol. 54, no. 1, pp. 83–87, 1997.
  119. H. R. Andersen, L. Thuesen, J. P. Bagger, T. Vesterlund, and P. E. Thomsen, “Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome,” Lancet, vol. 344, no. 8936, pp. 1523–1528, 1994. View at Publisher · View at Google Scholar
  120. A. J. Greenspon, R. G. Hart, D. Dawson et al., “Predictors of stroke in patients paced for sick sinus syndrome,” Journal of the American College of Cardiology, vol. 43, no. 9, pp. 1617–1622, 2004. View at Publisher · View at Google Scholar · View at PubMed
  121. E. B. Sgarbossa, S. L. Pinski, J. D. Maloney et al., “Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities,” Circulation, vol. 88, no. 3, pp. 1045–1053, 1993.
  122. P. Lechat, J. L. Mas, G. Lascault et al., “Prevalence of patent foramen ovale in patients with stroke,” New England Journal of Medicine, vol. 318, no. 18, pp. 1148–1152, 1988.
  123. M. Di Tullio, R. L. Sacco, A. Gopal, J. P. Mohr, and S. Homma, “Patent foramen ovale as a risk factor for cryptogenic stroke,” Annals of Internal Medicine, vol. 117, no. 6, pp. 461–465, 1992.
  124. M. Knauth, S. Ries, S. Pohimann et al., “Cohort study of multiple brain lesions in sport divers: role of a patent foramen ovale,” British Medical Journal, vol. 314, no. 7082, pp. 701–705, 1997.
  125. G. P. Anzola, M. Magoni, M. Guindani, L. Rozzini, and G. Dalla Volta, “Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study,” Neurology, vol. 52, no. 8, pp. 1622–1625, 1999.
  126. J. R. Overell, I. Bone, and K. R. Lees, “Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies,” Neurology, vol. 55, no. 8, pp. 1172–1179, 2000.
  127. C. Lamy, C. Giannesini, M. Zuber et al., “Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm,” Stroke, vol. 33, no. 3, pp. 706–711, 2002. View at Publisher · View at Google Scholar
  128. E. A. Wammes-van der Heijden, C. C. Tijssen, and A. C. Egberts, “Right-to-left shunt and migraine: the strength of the relationship,” Cephalalgia, vol. 26, no. 2, pp. 208–213, 2006. View at Publisher · View at Google Scholar · View at PubMed
  129. R. H. Falk, “PFO or UFO? The role of a patent foramen ovale in cryptogenic stroke,” American Heart Journal, vol. 121, no. 4, part 1, pp. 1264–1266, 1991.
  130. M. Schwerzmann, C. Seiler, E. Lipp et al., “Relation between directly detected patent foramen ovale and ischemic brain lesions in sport divers,” Annals of Internal Medicine, vol. 134, no. 1, pp. 21–24, 2001.
  131. N. Maalikjy Akkawi, C. Agosti, G. P. Anzola et al., “Transient global amnesia: a clinical and sonographic study,” European Neurology, vol. 49, no. 2, pp. 67–71, 2003. View at Publisher · View at Google Scholar · View at PubMed
  132. I. Meissner, B. K. Khandheria, J. A. Heit et al., “Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study,” Journal of the American College of Cardiology, vol. 47, no. 2, pp. 440–445, 2006. View at Publisher · View at Google Scholar · View at PubMed
  133. G. W. Petty, B. K. Khandheria, I. Meissner et al., “Population-based study of the relationship between patent foramen ovale and cerebrovascular ischemic events,” Mayo Clinic Proceedings, vol. 81, no. 5, pp. 602–608, 2006. View at Publisher · View at Google Scholar
  134. J. L. Mas, C. Arquizan, C. Lamy et al., “Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both,” New England Journal of Medicine, vol. 345, no. 24, pp. 1740–1746, 2001. View at Publisher · View at Google Scholar · View at PubMed
  135. J. E. Lock, “Patent foramen ovale is indicted, but the case hasn't gone to trial,” Circulation, vol. 101, no. 8, p. 838, 2000.
  136. R. K. Deeik, R. M. Thomas, P. Sakiyalak, S. Botkin, B. Blakeman, and M. Bakhos, “Minimal access closure of patent foramen ovale: is it also recommended for patients with paradoxical emboli?” Annals of Thoracic Surgery, vol. 74, no. 4, pp. S1326–S1329, 2002.
  137. J. Serena, T. Segura, M. J. Perez-Ayuso, J. Bassaganyas, A. Molins, and A. Dávalos, “The need to quantify right-to-left shunt in acute ischemic stroke: a case-control study,” Stroke, vol. 29, no. 7, pp. 1322–1328, 1998.
  138. L. A. Wu, J. F. Malouf, J. A. Dearani et al., “Patent foramen ovale in cryptogenic stroke: current understanding and management options,” Archives of Internal Medicine, vol. 164, no. 9, pp. 950–956, 2004. View at Publisher · View at Google Scholar · View at PubMed
  139. S. Homma, R. L. Sacco, M. R. Di Tullio, R. R. Sciacca, and J. P. Mohr, “Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study,” Circulation, vol. 105, no. 22, pp. 2625–2631, 2002. View at Publisher · View at Google Scholar
  140. S. R. Messe, R. S. Schwartz, and J. K. Perloff, “Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of recurrent stroke in adults,” in UpToDate, B. D. Rose, Ed., UpToDate, Waltham, Mass, USA, 2006.
  141. J. Serena, J. Marti-Fàbregas, E. Santamarina et al., “Recurrent stroke and massive right-to-left shunt. Results from the prospective Spanish multicenter (CODICIA) study,” Stroke, vol. 39, no. 12, pp. 3131–3136, 2008. View at Publisher · View at Google Scholar · View at PubMed
  142. X. Ustrell, J. Serena, E. Santamarina, et al., “Massive right-to-left shunt is associated with good prognosis in patient with cryptogenic ischaemic stroke. Preliminary results from the CODICIA spanish multicentre study,” Cerebrovascular Diseases, vol. 19, supplement 2, p. 25, 2005.
  143. J. R. Kizer and R. B. Devereux, “Patent foramen ovale in young adults with unexplained stroke,” New England Journal of Medicine, vol. 353, no. 22, pp. 2361–2372, 2005. View at Publisher · View at Google Scholar · View at PubMed
  144. S. R. Messé, I. E. Silverman, J. R. Kizer et al., “Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 62, no. 7, pp. 1042–1050, 2004.
  145. R. L. Sacco, R. Adams, G. Albers et al., “Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline,” Circulation, vol. 113, no. 10, pp. e409–e449, 2006. View at Publisher · View at Google Scholar · View at PubMed
  146. Cerebral Embolism Task Force, “Cardiogenic brain embolism,” Archives of Neurology, vol. 43, no. 1, pp. 71–84, 1986.
  147. Cerebral Embolism Task Force, “Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force,” Archives of Neurology, vol. 46, no. 7, pp. 727–743, 1989.
  148. A. A. Pruitt, R. H. Rubin, A. W. Karchmer, and G. W. Duncan, “Neurologic complications of bacterial endocarditis,” Medicine, vol. 57, no. 4, pp. 329–343, 1978.
  149. W. R. Gransden, S. J. Eykyn, and R. M. Leach, “Neurological presentations of native valve endocarditis,” Quarterly Journal of Medicine, vol. 73, no. 272, pp. 1135–1142, 1989.
  150. A. V. Salgado, A. J. Furlan, T. F. Keys, T. R. Nichols, and G. J. Beck, “Neurologic complications of endocarditis: a 12-year experience,” Neurology, vol. 39, no. 2, pp. 173–178, 1989.
  151. M. C. Kanter and R. G. Hart, “Neurologic complications of infective endocarditis,” Neurology, vol. 41, no. 7, pp. 1015–1020, 1991.
  152. A. A. Pruitt, “Neurologic complications of infective endocarditis. Review of an evolving disease and its management issues in the 1990s,” Neurologist, vol. 1, pp. 20–34, 1995.
  153. M. Heiro, J. Nikoskelainen, E. Engblom, E. Kotilainen, R. Marttila, and P. Kotilainen, “Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland,” Archives of Internal Medicine, vol. 160, no. 18, pp. 2781–2787, 2000.
  154. E. Mylonakis and S. B. Calderwood, “Infective endocarditis in adults,” New England Journal of Medicine, vol. 345, no. 18, pp. 1318–1330, 2001. View at Publisher · View at Google Scholar · View at PubMed
  155. B. Stilhart, J. Aboulker, F. Khouadja, D. Robine, O. Ouahes, and A. Redondo, “Should the aneurysms of Osler's disease be investigated and operated on prior to hemorrhage?” Neurochirurgie, vol. 32, no. 5, pp. 410–417, 1986.
  156. J. A. Lopez, R. S. Ross, M. C. Fishbein, and R. J. Siegel, “Nonbacterial thrombotic endocarditis: a review,” American Heart Journal, vol. 113, no. 3, pp. 773–784, 1987.
  157. N. Futrell and C. Millikan, “Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus,” Stroke, vol. 20, no. 5, pp. 583–591, 1989.
  158. A. Fluture, S. Chaudhari, and W. H. Frishman, “Valvular heart disease and systemic lupus erythematosus: therapeutic implications,” Heart Disease, vol. 5, no. 5, pp. 349–353, 2003. View at Publisher · View at Google Scholar · View at PubMed
  159. P. A. Sandercock, C. Counsell, and A. K. Kamal, “Anticoagulants for acute ischaemic stroke,” Cochrane Database of Systematic Reviews, vol. 8, no. 4, Article ID CD000024, 2008. View at Publisher · View at Google Scholar · View at PubMed
  160. M. Paciaroni, G. Agnelli, S. Micheli, and V. Caso, “Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke. A Meta-Analysis of Randomized Controlled Trial,” Stroke, vol. 38, no. 2, pp. 423–430, 2007. View at Publisher · View at Google Scholar · View at PubMed
  161. M. Camerlingo, P. Salvi, G. Belloni, T. Gamba, B. M. Cesana, and A. Mamoli, “Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions,” Stroke, vol. 36, no. 11, pp. 2415–2420, 2005. View at Publisher · View at Google Scholar · View at PubMed
  162. R. Saxena, S. Lewis, E. Berge, P. A. G. Sandercock, and P. J. Koudstaal, “Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial,” Stroke, vol. 32, no. 10, pp. 2333–2337, 2001.
  163. Cerebral Embolism Study Group, “Immediate anticoagulation of embolic stroke: a randomized trial,” Stroke, vol. 14, no. 5, pp. 668–676, 1983.
  164. P. M. Bath, E. Lindenstrom, G. Boysen et al., “Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial,” Lancet, vol. 358, no. 9283, pp. 702–710, 2001. View at Publisher · View at Google Scholar
  165. E. Berge, M. Abdelnoor, P. H. Nakstad, and P. M. Sandset, “Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group,” Lancet, vol. 355, no. 9211, pp. 1205–1210, 2000.
  166. M. Hommel, “Fraxiparine in Ischemic Stroke Study (FISS bis),” Cerebrovascular disease, vol. 8, supplement 4, p. 19, 1998.
  167. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators, “Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial,” Journal of the American Medical Association, vol. 279, no. 16, pp. 1265–1272, 1998. View at Publisher · View at Google Scholar
  168. H. Yu, E. M. Muñoz, R. E. Edens, and R. J. Linhardt, “Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance,” Biochimica et Biophysica Acta, vol. 1726, no. 2, pp. 168–176, 2005. View at Publisher · View at Google Scholar · View at PubMed
  169. D. Pevni, I. Frolkis, I. Shapira et al., “Heparin added to cardioplegic solution inhibits tumor necrosis factor-alpha production and attenuates myocardial ischemic-reperfusion injury,” Chest, vol. 128, no. 3, pp. 1805–1811, 2005. View at Publisher · View at Google Scholar · View at PubMed
  170. C. T. Esmon, “Inflammation and thrombosis,” Journal of Thrombosis and Haemostasis, vol. 1, no. 7, pp. 1343–1348, 2003.
  171. A. Vignoli, M. Marchetti, D. Balducci, T. Barbui, and A. Falanga, “Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties,” Haematologica, vol. 91, no. 2, pp. 207–214, 2006.
  172. Á. Cervera, C. Justicia, J. C. Reverter, A. M. Planas, and Á. Chamorro, “Steady plasma concentration of unfractionated heparin reduces infarct volume and prevents inflammatory damage after transient focal cerebral ischemia in the rat,” Journal of Neuroscience Research, vol. 77, no. 4, pp. 565–572, 2004. View at Publisher · View at Google Scholar · View at PubMed
  173. R. G. Hart, S. Palacio, and L. A. Pearce, “Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials,” Stroke, vol. 33, no. 11, pp. 2722–2727, 2002. View at Publisher · View at Google Scholar
  174. International Stroke Trial Collaborative Group, “The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke,” Lancet, vol. 349, no. 9065, pp. 1569–1581, 1997. View at Publisher · View at Google Scholar
  175. CAST (Chinese Acute Stroke Trial) Collaborative Group, “CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke,” Lancet, vol. 349, no. 9066, pp. 1641–1649, 1997. View at Publisher · View at Google Scholar
  176. E. Berge, M. Abdelnoor, P. H. Nakstad, and P. M. Sandset, “Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study,” Lancet, vol. 355, no. 9211, pp. 1205–1210, 2000.
  177. R. Saxena, S. Lewis, E. Berge, P. A. G. Sandercock, and P. J. Koudstaal, “Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial,” Stroke, vol. 32, no. 10, pp. 2333–2337, 2001.
  178. R. Kay, K. S. Wong, Y. L. Yu et al., “Low-molecular-weight heparin for the treatment of acute ischemic stroke,” New England Journal of Medicine, vol. 333, no. 24, pp. 1588–1593, 1995. View at Publisher · View at Google Scholar
  179. K. S. Wong, C. Chen, P. W. Ng et al., “Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study,” Lancet Neurology, vol. 6, no. 5, pp. 407–413, 2007. View at Publisher · View at Google Scholar · View at PubMed
  180. H. C. Diener, E. B. Ringelstein, R. Von Kummer et al., “Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators,” Stroke, vol. 32, no. 1, pp. 22–29, 2001.
  181. P. M. Bath, E. Lindenstrom, G. Boysen et al., “Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial,” Lancet, vol. 358, no. 9283, pp. 702–710, 2001. View at Publisher · View at Google Scholar
  182. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators, “Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial,” Journal of the American Medical Association, vol. 279, no. 16, pp. 1265–1272, 1998. View at Publisher · View at Google Scholar
  183. G. Gubitz, P. Sandercock, and C. Counsell, “Anticoagulants for acute ischaemic stroke,” Cochrane database of systematic reviews, no. 3, Article ID CD000024, 2004.
  184. M. Camerlingo, P. Salvi, G. Belloni, T. Gamba, B. M. Cesana, and A. Mamoli, “Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions,” Stroke, vol. 36, no. 11, pp. 2415–2420, 2005. View at Publisher · View at Google Scholar · View at PubMed
  185. A. Chamorro, O. Busse, V. Obach et al., “The rapid anticoagulation prevents ischemic damage study in acute stroke—final results from the writing committee,” Cerebrovascular Diseases, vol. 19, no. 6, pp. 402–404, 2005. View at Publisher · View at Google Scholar · View at PubMed
  186. A. Chamorro, “Immediate anticoagulation for acute stroke in atrial fibrillation: yes,” Stroke, vol. 37, no. 12, pp. 3052–3053, 2006. View at Publisher · View at Google Scholar · View at PubMed
  187. P. Sandercock, “Immediate anticoagulation for acute stroke in atrial fibrillation: no,” Stroke, vol. 37, no. 12, pp. 3054–3055, 2006. View at Publisher · View at Google Scholar · View at PubMed
  188. “Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack,” Lancet, vol. 358, no. 9287, pp. 1033–1041, 2001. View at Publisher · View at Google Scholar · View at PubMed
  189. H. C. O'Donnell, J. Rosand, K. A. Knudsen et al., “Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage,” New England Journal of Medicine, vol. 342, no. 4, pp. 240–245, 2000. View at Publisher · View at Google Scholar
  190. M. H. Eckman, J. Rosand, K. A. Knudsen, D. E. Singer, and S. M. Greenberg, “Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis,” Stroke, vol. 34, no. 7, pp. 1710–1716, 2003. View at Publisher · View at Google Scholar · View at PubMed
  191. J. O. Donaldson and N. S. Lee, “Arterial and venous stroke associated with pregnancy,” in Neurologic Clinics. Neurologic Complications of Pregnanc, M. Yerby and O. Devinsky, Eds., pp. 583–599, W. B. Saunders, Philadelphia, Pa, USA, 1994.
  192. I. Iturbe-Alessio, M. C. Fonseca, O. Mutchinik, M. A. Santos, A. Zajarías, and E. Salazar, “Risks of anticoagulant therapy in pregnant women with artificial heart valves,” New England Journal of Medicine, vol. 315, no. 22, pp. 1390–1393, 1986.
  193. E. Sbarouni and C. M. Oakley, “Outcome of pregnancy in women with valve prostheses,” British Heart Journal, vol. 71, no. 2, pp. 196–201, 1994.
  194. L. Hung and S. H. Rahimtoola, “Prosthetic heart valves and pregnancy,” Circulation, vol. 107, no. 9, pp. 1240–1246, 2003. View at Publisher · View at Google Scholar
  195. V. Wong, C. H. Cheng, and K. C. Chan, “Fetal and neonatal outcome of exposure to anticoagulants during pregnancy,” American Journal of Medical Genetics, vol. 45, no. 1, pp. 17–21, 1993. View at Publisher · View at Google Scholar · View at PubMed
  196. J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin, “American Heart Association/American College of Cardiology Foundation guide to warfarin therapy,” Journal of the American College of Cardiology, vol. 41, no. 9, pp. 1633–1652, 2003. View at Publisher · View at Google Scholar
  197. J. S. Ginsberg and J. Hirsh, “Use of antithrombotic agents during pregnancy,” Chest, vol. 108, supplement 4, pp. 305S–311S, 1995.
  198. C. S. Landefeld and R. J. Beyth, “Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention,” American Journal of Medicine, vol. 95, no. 3, pp. 315–328, 1993. View at Publisher · View at Google Scholar
  199. J. Hirsh, C. Kearon, and J. Ginsberg, “Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia,” Archives of Internal Medicine, vol. 157, no. 19, pp. 2174–2177, 1997.
  200. F. J. van der Meer, F. R. Rosendaal, J. P. Vandenbroucke, and E. Briet, “Bleeding complications in oral anticoagulant therapy. An analysis of risk factors,” Archives of Internal Medicine, vol. 153, no. 13, pp. 1557–1562, 1993. View at Publisher · View at Google Scholar
  201. A. Odén, M. Fahlén, and R. G. Hart, “Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal,” Thrombosis Research, vol. 117, no. 5, pp. 493–499, 2006. View at Publisher · View at Google Scholar · View at PubMed
  202. S. D. Fihn, M. McDonell, D. Martin et al., “Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin optimized outpatient follow-up study group,” Annals of Internal Medicine, vol. 118, no. 7, pp. 511–520, 1993.
  203. “Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials,” Archives of Internal Medicine, vol. 154, no. 13, pp. 1449–1457, 1994. View at Publisher · View at Google Scholar
  204. T. Steiner, J. Rosand, and M. Diringer, “Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions,” Stroke, vol. 37, no. 1, pp. 256–262, 2006. View at Publisher · View at Google Scholar · View at PubMed
  205. N. L. Smith, B. M. Psaty, C. D. Furberg et al., “Temporal trends in the use of anticoagulants among older adults with atrial fibrillation,” Archives of Internal Medicine, vol. 159, no. 14, pp. 1574–1578, 1999. View at Publisher · View at Google Scholar
  206. C. Morocutti, G. Amabile, F. Fattapposta et al., “Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators,” Stroke, vol. 28, no. 5, pp. 1015–1021, 1997.
  207. M. G. Bousser, J. Bouthier, H. R. Buller, et al., “Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial,” Lancet, vol. 371, no. 9609, pp. 315–321, 2008.
  208. P. Kakar, T. Watson, and G. Y. Lip, “Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X,” Current Opinion in Investigational Drugs, vol. 8, no. 3, pp. 256–265, 2007.
  209. S. Ndegwa, K. Moulton, and C. Argáez, Dabigatran or Rivaroxaban Versus Other Anticoagulants for Thromboprophylaxis after Major Orthopedic Surgery: Systematic Review of Comparative Clinical-Effectiveness and Safety, Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada, 2009.
  210. B. I. Eriksson, D. J. Quinlan, and J. I. Weitz, “Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development,” Clinical Pharmacokinetics, vol. 48, no. 1, pp. 1–22, 2009. View at Publisher · View at Google Scholar
  211. J. I. Weitz and S. M. Bates, “New anticoagulants,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1843–1853, 2005. View at Publisher · View at Google Scholar · View at PubMed
  212. “Heparin: unfractionated [CPhA monograph],” in eCPS [database online], Canadian Pharmacists Association, Ottawa, Canada, 2005.
  213. “Aldocumar (warfarin sodium): product monograph,” Vademcum: Aldo-Union, Spain, 2010.
  214. “Pradaxa (dabigatran etexilate) : product monograph,” Vademcum: Boehringer, Ingelheim Spain, 2010.
  215. “Xarelto (rivaroxaban) : product monograph,” Vademcum: Bayer, Spain, 2010.
  216. “Clexane (enoxaparin sodium): product monograph,” Vademcum: Sanofi-aventis, Spain, 2010.
  217. “Fragmin (dalteparin sodium): product monograph,” Vademcum: Pfizer, Spain, 2010.
  218. D. Garcia, E. Libby, and M. A. Crowther, “The new oral anticoagulants,” Blood, vol. 115, no. 1, pp. 15–20, 2010. View at Publisher · View at Google Scholar · View at PubMed
  219. G. J. Hankey and J. W. Eikelboom, “Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events,” The Lancet Neurology, vol. 9, no. 3, pp. 273–284, 2010. View at Publisher · View at Google Scholar
  220. S. B. Olsson, “Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial,” Lancet, vol. 362, no. 9397, pp. 1691–1698, 2003. View at Publisher · View at Google Scholar
  221. G. W. Albers, H. C. Diener, L. Frison, et al., “Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial,” Journal of the American Medical Association, vol. 293, no. 6, pp. 690–698, 2005. View at Publisher · View at Google Scholar · View at PubMed
  222. C. L. O'Brien and B. F. Gage, “Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation,” Journal of the American Medical Association, vol. 293, no. 6, pp. 699–706, 2005. View at Publisher · View at Google Scholar · View at PubMed
  223. V. Gurewich, “Ximelagatran—promises and concerns,” Journal of the American Medical Association, vol. 293, no. 6, pp. 736–739, 2005. View at Publisher · View at Google Scholar · View at PubMed
  224. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar · View at PubMed
  225. B. F. Gage, “Can we rely on RE-LY?” New England Journal of Medicine, vol. 361, no. 12, pp. 1200–1202, 2009. View at Publisher · View at Google Scholar · View at PubMed
  226. “Clot drug 'cold save thousands',” 2008, BBC News Online (BBC)http://news.bbc.co.uk/2/hi/health/7354818.stm.
  227. ROCKET AF Study Investigators, “Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study,” American Heart Journal, vol. 159, no. 3, article e1, pp. 340–347, 2010.
  228. J. L. Cox, J. P. Boineau, R. B. Schuessler, R. D. B. Jaquiss, and D. G. Lappas, “Modification of the Maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results,” Journal of Thoracic and Cardiovascular Surgery, vol. 110, no. 2, pp. 473–484, 1995. View at Publisher · View at Google Scholar
  229. S. H. Ostermayer, M. Reisman, P. H. Kramer et al., “Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials,” Journal of the American College of Cardiology, vol. 46, no. 1, pp. 9–14, 2005. View at Publisher · View at Google Scholar · View at PubMed